TABLE 2.

BEI, in vitro intrinsic Cl_biliary, and predicted Cl_biliary compared with estimated in vivo hepatic clearance for selected ARBs and HMG-CoA reductase inhibitors in humans

Data represent mean ± S.E.M. of three individual experiments in triplicate.

Compound	BEI	In Vitro Intrinsic Clbiliary	Plasma Unbound Fraction	Predicted Clbiliary	Estimated In Vivo Hepatic Clearance
	%	ml/min/kga	fu,p	ml/min/kgb	ml/min/kgc
Olmesartan	34.6 ± 3.0	0.943 ± 0.330	0.01d	0.00942 ± 0.00329	0.205
Valsartan	23.0 ± 3.4	1.20 ± 0.33	0.059e	0.0702 ± 0.0193	0.370
Pravastatin	30.9 ± 3.1	0.484 ± 0.061	0.5f	0.237 ± 0.029	7.20
Rosuvastatin	24.6 ± 4.7	3.39 ± 0.89	0.12g	0.390 ± 0.098	8.38
Pitavastatin	15.6 ± 2.7	5.48 ± 1.21	0.004h	0.0219 ± 0.0048	No data

^aIn vitro intrinsic Cl_biliary values were calculated according to eq. 2.

^bPredicted Cl_biliary values were calculated according to eq. 3.

^cEstimated in vivo hepatic clearance values were calculated based on the difference between total clearance and renal clearance (see Materials and Methods).

^dNakagomi-Hagihara et al., 2006.

^eColussi et al., 1997.

^fNakagomi-Hagihara et al., 2007.

^gRosuvastatin regulatory documentation.

^hPitavastatin regulatory documentation.